Overview
Allurion Technologies Inc., listed on the NYSE under the ticker symbol ALUR, is a company dedicated to addressing obesity through innovative medical, digital, and nutritional solutions. Founded in 2009 by Shantanu Gaur and Samuel Levy, then Harvard Medical School students, Allurion's mission is to end obesity globally by providing a comprehensive weight-loss program that empowers patients to make lifelong healthy choices. The core of Allurion's offering is the Allurion Program, which includes:
- Elipse Gastric Balloon: A swallowable, procedure-less intragastric balloon that helps patients lose 10-15% of their body weight in 16 weeks.
- AI-Powered Remote Patient Monitoring: Utilizing advanced technology for continuous patient care.
- Proprietary Behavior Change Program: Designed to help patients adopt and maintain healthy habits.
- Secure Messaging and Video Telehealth: Provided through the Allurion Virtual Care Suite. The Allurion Program is backed by clinical evidence, demonstrating its safety and efficacy. Over 100,000 balloons have been distributed worldwide, showing significant weight loss results and improvements in metabolic syndrome. Headquartered in Natick, Massachusetts, Allurion Technologies is led by Dr. Shantanu Gaur, who serves as the Co-Founder, CEO, President, and Principal Financial and Accounting Officer. The company is recognized as a great place to work, with 85% of employees stating it is a positive work environment. Operating in the healthcare sector, specifically within the medical devices industry, Allurion has approximately 504 employees globally. The company is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol ALUR and actively files with the SEC, including recent amendments to their registration of securities.
Leadership Team
Allurion Technologies boasts a diverse and experienced leadership team driving its mission to end obesity. Key members include: CEO and Founder
- Shantanu Gaur: Co-founder and CEO since 2018, Dr. Gaur holds an M.D. from Harvard Medical School and a B.S. in Biology from Harvard College. He has been with the company for over 15 years. Executive Leadership
- Chris Geberth: Chief Financial Officer
- Ram Chuttani: Chief Medical Officer, with a background as Director of Endoscopy at Beth Israel Deaconess Medical Center
- Ojas A. Buch: Chief Operating Officer, appointed in June 2024
- Brendan Gibbons: Chief Legal Officer and Corporate Secretary, appointed in January 2024 Board of Directors
- Douglas Hudson: Recently appointed, a serial healthcare entrepreneur with experience in consumer-facing healthcare ventures
- Michael Davin: Board member since October 2017, with experience as a director in various healthcare and technology companies
- Nicholas Lewin: Director with experience as an investor in innovative healthcare and medical device companies
- Keith Johns: Eli Lilly veteran, bringing extensive pharmaceutical industry experience Other Key Roles
- Tomer Stavitsky: Vice President of Corporate Development, focusing on M&A and partnership strategy in AI and digital health The leadership team combines deep expertise in healthcare, technology, and business management, positioning Allurion Technologies for continued growth and innovation in the weight loss and healthcare sectors.
History
Allurion Technologies, the company behind the innovative Allurion gastric balloon and comprehensive weight-loss program, has a rich history dating back to its founding in 2009. Founding and Early Years
- Founded in 2009 by Shantanu Gaur and Samuel Levy, then students at Harvard Medical School
- Driven by patient stories, the founders developed a more accessible and convenient weight-loss solution Product Development
- Created the Allurion Program, a full-stack weight-loss platform including:
- Allurion Balloon: A swallowable, procedure-less intragastric balloon
- Allurion Virtual Care Suite: AI-powered digital therapeutic and remote patient monitoring solution
- Proprietary behavior change program Regulatory Approvals and Clinical Studies
- Received CE-mark for the Allurion Balloon in 2015
- Conducted extensive clinical studies, demonstrating significant weight loss results Global Expansion
- Expanded operations to over 60 countries
- Treated more than 100,000 patients
- Launched in new markets including Canada, Mexico, India, Australia, and Brazil in 2022 Financial Growth and Public Listing
- Revenue growth from $20 million in 2020 to $64 million in 2022
- Announced business combination with Compute Health Acquisition Corp in February 2023
- Became publicly listed on the New York Stock Exchange under the symbol 'ALUR' Leadership and Board Development
- Dr. Shantanu Gaur serves as CEO
- Board of directors includes experienced professionals from various sectors Allurion Technologies continues to innovate and expand its reach, addressing one of the world's largest unmet medical needs through its mission to end obesity globally.
Products & Solutions
Allurion Technologies offers a comprehensive suite of products and solutions aimed at addressing obesity and promoting long-term weight loss:
Allurion Program
The core offering combines medical, digital, and nutritional approaches to weight loss:
- Allurion Gastric Balloon (Elipse™): A swallowable, procedure-less intragastric balloon that helps patients lose 10-15% of their body weight in 16 weeks. This non-invasive solution addresses the need for weight loss without traditional surgery.
AllurionMeds
A recently launched program integrating GLP-1 medications with AI-powered support:
- GLP-1 Medications: Sourced from FDA-registered 503b facilities and delivered directly to patients' homes.
- Coach Iris: An AI-native platform providing 24/7 coaching and support for medication adherence and healthy behaviors.
- Virtual Dietician Access: Patients can consult with dieticians virtually to support their weight loss journey.
- Connected Smart Scale: Measures weight, muscle, and bone mass for comprehensive monitoring.
Allurion Virtual Care Suite
A set of digital tools supporting weight loss and health management:
- Allurion Mobile App: Provides ongoing support and tracking for consumers.
- Allurion Insights: Offers healthcare providers tools to customize, monitor, and manage patient weight loss therapy.
- Allurion Connected Scale: Integrates with the mobile app and AI platform for comprehensive health metrics.
Additional Features
- Expanded Services: Available in all 50 U.S. states with plans to offer a broader range of GLP-1 medications.
- Clinical Research: The Allurion Program is backed by extensive studies on safety and efficacy. Allurion Technologies' holistic approach combines innovative medical technologies with digital and nutritional support, aiming to help patients achieve and maintain significant weight loss.
Core Technology
Allurion Technologies' core technology revolves around its comprehensive weight loss platform, the Allurion Program. Key components include:
Allurion Balloon
The world's first and only swallowable, procedure-less intragastric balloon for weight loss. This innovative device:
- Is ingested orally and expands in the stomach
- Helps reduce hunger and facilitate weight loss
- Requires no surgery or endoscopy
Virtual Care Suite (VCS)
An AI-powered digital therapeutic and remote patient monitoring solution comprising:
- Allurion App:
- Provides access to a proprietary behavior change program
- Offers over 150 weight loss actions related to diet, nutrition, mental health, sleep, and goal setting
- Available in over 15 languages
- Allurion Insights:
- Clinic dashboard for healthcare providers
- Offers end-to-end remote patient monitoring
- Utilizes AI-powered tools, including the Iris AI platform
- Leverages machine learning for key insights and workflow streamlining
- Connected Scale and Health Tracker:
- Monitors weight, body fat, activity, sleep, and other critical metrics
- Integrates data into the Allurion App and VCS
AI-Enabled Support
- Coach Iris: Part of the AllurionMeds program
- Combines GLP-1 medications with virtual dietician access
- Provides AI-driven coaching for long-term weight maintenance
Integrated Care
The Allurion Program integrates:
- Secure messaging
- Video telehealth visits
- Remote patient monitoring
- Treatment tracking
- Clinic-led onboarding These features support various weight loss treatments, including gastric balloons, surgery, and medications. Allurion Technologies' core technology uniquely combines innovative medical devices, AI-powered digital therapeutics, and comprehensive patient support to create a holistic weight loss platform.
Industry Peers
Allurion Technologies operates in the medical equipment and supplies industry, competing with several notable companies:
Direct Competitors
- Sensus Healthcare (NASDAQ: SRTS): Focused on radiation oncology and non-invasive treatments
- TELA Bio (NASDAQ: TELA): Develops tissue reinforcement materials
- electroCore (NASDAQ: ECOR): Specializes in non-invasive vagus nerve stimulation therapies
- LENSAR (NASDAQ: LNSR): Develops laser cataract surgery systems
- Fractyl Health (private): Creates minimally invasive interventions for metabolic diseases
- FONAR (NASDAQ: FONR): Known for MRI technology, particularly the UPRIGHT MRI
- Monogram Orthopaedics (private): Develops personalized orthopedic implants
- Edap Tms (NASDAQ: EDAP): Specializes in minimally invasive medical devices for urology and oncology
- Milestone Scientific (NYSE: MLSS): Develops dental and medical injection technologies
- Vivani Medical (private): Focuses on various therapeutic areas
Other Industry Peers
- MED-EL: Develops cochlear implants and hearing solutions
- Otto Bock HealthCare: Specializes in prosthetics, orthotics, and mobility solutions
- Smith & Nephew: Multinational company offering orthopedics, sports medicine, and advanced wound management products
- Terumo Medical: Develops medical devices including cardiovascular systems and general hospital products
- IRIDEX (NASDAQ: IRIX): Focuses on ophthalmic laser-based medical products
- DarioHealth (NASDAQ: DRIO): Develops digital health solutions for chronic conditions
- Beyond Air (NASDAQ: XAIR): Specializes in nitric oxide-based therapies for respiratory diseases These companies operate within the broader medical equipment and supplies sector, often competing or complementing Allurion Technologies in various market segments. While some focus on specific areas like orthopedics or ophthalmology, others offer a range of medical solutions that may overlap with Allurion's weight loss and health monitoring technologies.